BEN 28010
Alternative Names: BEN-28010Latest Information Update: 01 Jan 2024
At a glance
- Originator BenevolentAI
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 28 Dec 2023 BenevolentAI plans to submit investigational new drug (IND) for Glioblastoma multiforme in early 2024
- 04 Oct 2022 BenevolentAI plans to file a clinical trial application (CTA) with the regulatory body for glioblastoma in 2023
- 27 Sep 2022 BEN 28010 is available for licensing as of 27 Sep 2022. https://www.benevolent.com/ (BenevolentAI website, September 2022)